Eli Lilly & Co. (LLY)

110.52 +0.29 (0.26%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/6/19 *Est.)
- M&A (3/31/19 *Est)

Latest Headlines

Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health August 14, 2019 6:45 AM - PR NewsWire Form 10-Q Elanco Animal Health For: Jun 30 August 13, 2019 4:20 PM - SEC Filing Eli Lilly & Co. (LLY) Reports Taltz (ixekizumab) Met Primary & All Major Secondary Endpoints up to Week 12 in Ph. 4 IXORA-R Study August 13, 2019 6:48 AM - StreetInsider Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living wi August 13, 2019 6:45 AM - PR NewsWire Form 8-K Elanco Animal Health For: Aug 13 August 13, 2019 6:37 AM - SEC Filing Elanco Animal Health Reports Second Quarter Results, Including Strong EPS and Gross Margin Improvement August 13, 2019 6:30 AM - BizWire Form 8-K Elanco Animal Health For: Aug 08 August 9, 2019 5:16 PM - SEC Filing Eli Lilly & Co. (LLY) Announces U.S. Court of Appeals Rules in Favor of it in Alimta Alternate Salt Form Patent Lawsuit August 9, 2019 12:18 PM - StreetInsider U.S. Court of Appeals Rules in Favor of Lilly in Alimta Alternate Salt Form Patent Lawsuit August 9, 2019 12:17 PM - PR NewsWire Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia August 8, 2019 6:45 AM - PR NewsWire Eli Lilly & Co. (LLY) Announces Leadership Changes in Corporate Business Development, Oncology R&D, and Managed Healthcare Services August 7, 2019 6:50 AM - StreetInsider Lilly Announces Leadership Changes in Corporate Business Development, Oncology R&D, and Managed Healthcare Services August 7, 2019 6:45 AM - PR NewsWire Lilly (LLY) Announces Positive Results for Emgality from CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments August 5, 2019 6:47 AM - StreetInsider Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments August 5, 2019 6:45 AM - PR NewsWire Form 10-Q LILLY ELI & CO For: Jun 30 August 2, 2019 12:48 PM - SEC Filing Elanco Animal Health (ELAN) Announces Acquisition of Prevtec Microbia Swine Vaccine Company August 1, 2019 8:19 AM - StreetInsider Elanco Announces Acquisition of Prevtec Microbia Swine Vaccine Company August 1, 2019 6:30 AM - BizWire Blue-blooded crabs at heart of pharma dispute on drug testing August 1, 2019 2:05 AM - StreetInsider Amgen results beat estimates, lung cancer trial planned July 30, 2019 5:05 PM - StreetInsider Form 8-K LILLY ELI & CO For: Jul 30 July 30, 2019 11:28 AM - SEC Filing Newer drugs help Eli Lilly top Wall Street quarterly profit estimate July 30, 2019 6:42 AM - StreetInsider Eli Lilly & Co. (LLY) Tops Q2 EPS by 5c, Revenue Beats, Updates FY Guidance July 30, 2019 6:27 AM - StreetInsider Lilly Reports Second-Quarter 2019 Financial Results, Raises 2019 EPS Guidance July 30, 2019 6:25 AM - PR NewsWire Eli Lilly & Co. (LLY) Announces Verzenio Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 July 30, 2019 6:14 AM - StreetInsider Lilly's Verzenio® (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 July 30, 2019 6:00 AM - PR NewsWire Eli Lilly & Co. (LLY) option implied volatility priced movement July 29, 2019 10:55 AM - StreetInsider Eli Lilly & Co. (LLY) weekly option implied volatility elevated into EPS and outlook July 26, 2019 10:45 AM - StreetInsider BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA July 24, 2019 11:19 PM - PR NewsWire Form 8-K Elanco Animal Health For: Jul 18 July 18, 2019 8:47 AM - SEC Filing Elanco Finalizes Acquisition of Aratana Therapeutics July 18, 2019 8:31 AM - BizWire AC Immune SA (ACIU) Commences Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer July 17, 2019 7:02 AM - StreetInsider AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease July 17, 2019 7:00 AM - Globe NewsWire Form 4 LILLY ELI & CO For: Jul 15 Filed by: Walker Karen July 16, 2019 11:25 AM - SEC Filing Form 4 LILLY ELI & CO For: Jul 15 Filed by: TAI JACKSON P July 16, 2019 11:22 AM - SEC Filing Form 4 LILLY ELI & CO For: Jul 15 Filed by: LUCIANO JUAN R July 16, 2019 11:19 AM - SEC Filing Form 4 LILLY ELI & CO For: Jul 15 Filed by: Alvarez Ralph July 16, 2019 11:17 AM - SEC Filing Form 4 LILLY ELI & CO For: Jul 15 Filed by: Smiley Joshua L July 15, 2019 3:47 PM - SEC Filing Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study July 13, 2019 6:45 AM - PR NewsWire Eli Lilly & Co. (LLY) option implied volatility elevated as shares sell off 2.9% July 12, 2019 10:24 AM - StreetInsider Eli Lilly & Co. (LLY) Adds to Yesterday's Losses, Down 3.8% July 12, 2019 9:41 AM - StreetInsider Lilly's (LLY) OVERCOME Observational Study Reveals Inconsistent and Sub-Optimal Treatment Landscape July 12, 2019 8:03 AM - StreetInsider Lilly's OVERCOME Observational Study Reveals Inconsistent and Sub-Optimal Treatment Landscape for Migraine July 12, 2019 8:00 AM - PR NewsWire Lilly (LLY) Presents Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality July 12, 2019 6:46 AM - StreetInsider AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality® (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migra July 12, 2019 6:45 AM - PR NewsWire Form 8-K LILLY ELI & CO For: Jul 11 July 11, 2019 10:59 AM - SEC Filing 111 Building "Fourth Sales Channel" to Support Pharmaceutical Companies and Accelerate Drug Distribution Outside of Hospitals July 11, 2019 10:57 AM - PR NewsWire Pfizer (PFE), Lilly (LLY) Merck (MRK) Shares Lower as Biotech Slumps July 11, 2019 9:40 AM - StreetInsider Pre-Open Movers 07/11: (IMUX) (OMER) (DVAX) (CI) (CVS) (WW) (SNSS) (BBBY) (FAST) (more...) July 11, 2019 8:55 AM - StreetInsider Lilly Announces Changes in Senior Leadership July 11, 2019 8:15 AM - PR NewsWire Lilly (LLY) Announces NEJM Publishes Positive Phase 3 Data for Emgality in Episodic Cluster Headache July 11, 2019 6:46 AM - StreetInsider New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache July 11, 2019 6:45 AM - PR NewsWire Lilly Announces Upcoming Presentation of New Data Indicating Rise in Opioid Use for Migraine Treatment July 10, 2019 2:15 PM - PR NewsWire Lilly Confirms Date and Conference Call for Second-Quarter 2019 Financial Results Announcement July 9, 2019 4:15 PM - PR NewsWire Exclusive: Germany's Bayer seeks animal health merger with Elanco - sources July 9, 2019 11:24 AM - StreetInsider Form 4 LILLY ELI & CO For: Jul 05 Filed by: Pusey Leigh Ann July 8, 2019 3:57 PM - SEC Filing Eli Lilly & Co. (LLY) option implied volatility at 19 July 8, 2019 5:45 AM - StreetInsider Form 425 Elanco Animal Health Filed by: ARATANA THERAPEUTICS, INC. July 2, 2019 4:39 PM - SEC Filing Elanco Announces R&D Collaboration with AgBiome for Swine Nutritional Health Innovation June 27, 2019 6:30 AM - BizWire UPDATE: Pfizer (PFE) Hits Low as Shares of Large Pharma Names Tank June 26, 2019 2:46 PM - StreetInsider Eli Lilly & Co. (LLY) Trades Near Low, Down 3.7% Amid Biotech Selloff June 26, 2019 12:06 PM - StreetInsider Lilly's (LLY) AWARD-11 trial studying higher investigational doses of Trulicity demonstrated superiority in A1C reduction in people with type 2 diabetes June 26, 2019 6:46 AM - StreetInsider Lilly's AWARD-11 trial studying higher investigational doses of Trulicity® (dulaglutide) demonstrated superiority in A1C reduction in people with type 2 diabetes June 26, 2019 6:45 AM - PR NewsWire Eli Lilly & Co. (LLY) Reports FDA Approval of Fast Track Designation for Empagliflozin for Treatment of Chronic Heart Failure June 26, 2019 6:05 AM - StreetInsider U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure June 26, 2019 6:00 AM - PR NewsWire Form 11-K LILLY ELI & CO For: Dec 31 June 24, 2019 4:19 PM - SEC Filing Eli Lilly & Co. (LLY) Declares $0.645 Quarterly Dividend; 2.2% Yield June 19, 2019 12:05 PM - StreetInsider Lilly Declares Third-Quarter 2019 Dividend June 19, 2019 12:05 PM - PR NewsWire Form 4 LILLY ELI & CO For: Jun 17 Filed by: Alvarez Ralph June 18, 2019 3:39 PM - SEC Filing Form 4 LILLY ELI & CO For: Jun 17 Filed by: LUCIANO JUAN R June 18, 2019 3:37 PM - SEC Filing Form 4 LILLY ELI & CO For: Jun 17 Filed by: TAI JACKSON P June 18, 2019 3:35 PM - SEC Filing Form 4 LILLY ELI & CO For: Jun 17 Filed by: Walker Karen June 18, 2019 3:35 PM - SEC Filing Form 424B3 Elanco Animal Health June 17, 2019 6:56 AM - SEC Filing Form EFFECT Elanco Animal Health June 17, 2019 6:02 AM - SEC Filing Lilly (LLY) Presents Positive Results for Taltz vs. Humira in Head-to-Head Superiority Study in Patients with Active Psoriatic Arthritis at EULAR June 14, 2019 6:46 AM - StreetInsider Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress June 14, 2019 6:45 AM - PR NewsWire Form S-4/A Elanco Animal Health June 12, 2019 4:08 PM - SEC Filing Lilly (LLY) to Present 5-Year Sustained Efficacy and Safety Results for Taltz in Patients with Plaque Psoriasis at WCD June 11, 2019 6:13 AM - StreetInsider Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology June 11, 2019 3:00 AM - PR NewsWire Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta® June 10, 2019 9:30 PM - PR NewsWire New analysis shows cardiorenal risk reductions of Jardiance® are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria June 10, 2019 1:00 PM - PR NewsWire Eli Lilly & Co. (LLY) Trades Off Worst Level, Still Down 2.8% June 10, 2019 10:28 AM - StreetInsider Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes June 9, 2019 7:30 PM - PR NewsWire Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions June 9, 2019 11:30 AM - PR NewsWire Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's® 79ᵗʰ Scientific Sessions® June 8, 2019 8:30 PM - PR NewsWire Lilly to Present New Data and Commitment to Patient-Centered Solutions at the Annual European Congress of Rheumatology June 6, 2019 6:45 AM - PR NewsWire Form 4 Elanco Animal Health For: Jun 03 Filed by: GARCIA ART A June 5, 2019 4:38 PM - SEC Filing Form 4 Elanco Animal Health For: Jun 03 Filed by: Meer James M June 5, 2019 4:35 PM - SEC Filing Form 4 LILLY ELI & CO For: Jun 05 Filed by: Smiley Joshua L June 5, 2019 2:16 PM - SEC Filing Lilly to Showcase Scientific Innovation within Dermatology Portfolio at 24th World Congress of Dermatology June 5, 2019 6:45 AM - PR NewsWire FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks June 4, 2019 9:01 PM - PR NewsWire FDA approves Lilly's (LLY) treatment for episodic cluster headache that reduces the frequency of attacks June 4, 2019 4:55 PM - StreetInsider Form 4 LILLY ELI & CO For: Jun 03 Filed by: Harrington Michael J June 4, 2019 1:57 PM - SEC Filing Lilly (LLY) Announces FDA Accepts NDA for Triple Combination Tablet for Adults with Type 2 Diabetes June 4, 2019 7:31 AM - StreetInsider U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes June 4, 2019 7:30 AM - PR NewsWire Eli Lilly & Co. (LLY) Shows Strength, Up 1.3% May 31, 2019 11:19 AM - StreetInsider Hurricane Season is Almost Here. Are You Ready? May 31, 2019 7:00 AM - PR NewsWire Lilly to Participate in Goldman Sachs Global Healthcare Conference May 30, 2019 4:15 PM - PR NewsWire Form S-4 Elanco Animal Health May 30, 2019 8:35 AM - SEC Filing Form EFFECT Elanco Animal Health May 30, 2019 6:02 AM - SEC Filing Lilly Announces Webcast to Discuss ADA Presentations and Diabetes Portfolio May 29, 2019 4:15 PM - PR NewsWire Form 424B3 Elanco Animal Health May 29, 2019 4:10 PM - SEC Filing Lilly (LLY) Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics May 28, 2019 7:55 AM - StreetInsider Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics May 28, 2019 7:54 AM - PR NewsWire Goldman Sachs Starts Eli Lilly (LLY) at Buy May 28, 2019 2:42 AM - StreetInsider Form 4 LILLY ELI & CO For: May 20 Filed by: Alvarez Ralph May 22, 2019 8:29 AM - SEC Filing Form 4 LILLY ELI & CO For: May 20 Filed by: LUCIANO JUAN R May 22, 2019 8:28 AM - SEC Filing Form 4 LILLY ELI & CO For: May 20 Filed by: TAI JACKSON P May 22, 2019 8:25 AM - SEC Filing Form 4 LILLY ELI & CO For: May 20 Filed by: Walker Karen May 22, 2019 8:23 AM - SEC Filing Lilly (LLY) Says Lower-Priced Insulin is Now Available May 22, 2019 6:38 AM - StreetInsider Lilly's Lower-Priced Insulin Now Available May 22, 2019 6:30 AM - PR NewsWire Eli Lilly & Co. (LLY) Reports Mirikizumab Met Primary Endpoint & Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions May 21, 2019 1:21 PM - StreetInsider Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions May 21, 2019 1:15 PM - PR NewsWire New Study Suggests Service Dogs Can Impact Psychosocial Health of Household May 21, 2019 7:00 AM - BizWire Full Article List